Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Outcome Technologies (COTI), the bioinformatics and accelerated drug discovery company, is pleased to announce that COTI-2, the Company's lead oncology asset, has received additional patent protection.
Subscribe to our email newsletter
The United States ("U.S.") Patent and Trademark Office has granted its sixth patent and the Japan Patent Office has granted its first patent for the Company’s lead oncology asset.
"We continue to pursue intellectual property coverage for COTI-2 and these recent patent grants strengthen our overall IP position," said Dr. Wayne Danter, President and CEO of COTI.
"In addition to the sixth U.S. patent and our first Japanese patent, we have several other patents pending for COTI-2 in major international markets. The continued development of our patent portfolio supports our ability to broadly protect our lead oncology asset, and reinforces our potential to maximize future commercial licensing opportunities."
U.S. Patent No. 8,822,475 extends and enhances the methods of treating cancers using compounds in the COTI-2 family covered under previous patent grants. Issuance of this patent strengthens the value of the COTI-2 franchise for licensing in the U.S. market.
Japanese Patent No. 5571387 covers the COTI-2 family of compounds, pharmaceutical preparations containing COTI-2, and methods of manufacturing the compounds.
This subject matter has previously been covered in patents received in the U.S. Issuance of the Japanese patent provides the Company with additional licensing opportunities for the COTI-2 franchise in Japanese and Asian markets.